Status:
COMPLETED
Open Label Safety Study of a Birch Pollen Allergen Extract
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Rhinoconjunctivitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This trial is performed to assess safety of a sublingual birch pollen extract.
Eligibility Criteria
Inclusion
- Allergic rhinoconjunctivitis attributable to birch pollen
- Positive SPT
- Positive EAST
Exclusion
- Serious chronic diseases
- Other perennial allergies
- Partly controlled asthma
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00818181
Start Date
June 1 2008
End Date
August 1 2010
Last Update
March 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. Nicolas Hunzelmann
Cologne, Germany, 50931